NASDAQ : INTS

Intensity Therapeutics, Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 3.34 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 10.90M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Details

NameIntensity Therapeutics, Inc.
SectorHealthcare
IndustryBiotechnology
Employees7
Founded2012
Ipo Date2023-06-30
CeoLewis Bender
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price5.00
IsinUS45828J2024
Cusip45828J202
Cik1567264
Sic2836
Stock TypeCommon Stock

Key executives

NameTitle
Lewis H. Bender M.A., M.B.A., M.S.Founder, President, Chief Executive Officer and Chairman of the Board
Joseph Talamo CPA, M.B.A.Chief Financial Officer
John Wesolowski CPA, M.B.A.Principal Accounting Officer and Controller
James M. AhlersExecutive Vice President of Corporate Finance

Contact

Address1 Enterprise Drive, Suite 430, Shelton, Connecticut 06484-4779, United States
Phone203 221 7381
Websitehttps://intensitytherapeutics.com